scholarly journals The Association of Coagulation Factor V (Leiden) and Factor II (Prothrombin) Mutations with Stroke

2014 ◽  
Vol 16 (11) ◽  
Author(s):  
Maryam Pirhoushiaran ◽  
Mohammad Reza Ghasemi ◽  
Javad Hami ◽  
Peyman Zargari ◽  
Payam Sasan nezhad ◽  
...  
1998 ◽  
Vol 80 (08) ◽  
pp. 344-345 ◽  
Author(s):  
Pasra Arnutti ◽  
Motofumi Hiyoshi ◽  
Wichai Prayoonwiwat ◽  
Oytip Nathalang ◽  
Chamaiporn Suwanasophon ◽  
...  

1996 ◽  
Vol 75 (02) ◽  
pp. 267-269 ◽  
Author(s):  
H Engel ◽  
L Zwang ◽  
H H D M van Vliet ◽  
J J Michiles ◽  
J Stibbe ◽  
...  

SummaryThe currently used activated Protein C resistance test demonstrated to be of limited diagnostic value for the detection of the mutant Factor V Leiden. Moreover, this assay is not useful for patients under anticoagulant therapy. A modification of the APC resistance test, applying Factor V deficient plasma is described which demonstrates a specificity and sensitivity of 1.0. The superiority of the modified APC resistance test over the existing APC resistance test was verified by genotyping.For that purpose, the Amplification Refractory Mutation System (ARMS) was applied to the detection of the G to A mutation at position 1691 in the gene encoding coagulation Factor V. The mutation at that position could be easily detected by using each of two allele-specific oligonucleotide primers concomitantly with one common primer in two separate polymerase chain reactions, thereby amplifying a fragment of 186 base-pairs of the Factor V gene.


2003 ◽  
Vol 1 ◽  
pp. P0861-P0861
Author(s):  
M. Procházka ◽  
C. Happach ◽  
K. Marsál ◽  
B. Dahlback ◽  
P. G. Lindqvist

1996 ◽  
Vol 76 (05) ◽  
pp. 735-737 ◽  
Author(s):  
Javier Corral ◽  
Juan A Iniesta ◽  
Rocio González-Conejero ◽  
Vicente Vicente

SummaryRecently, a point mutation in the coagulation Factor V gene (G to A in position 1691) has been identified which makes the mutant Factor V (called Factor V Leiden) resistant to activated protein C. This defect is a well established genetic risk factor in venous thrombosis. Because of the high prevalence of Factor V Leiden in normal population (2-7%), it would be reasonable to perform a rapid and simple method for screening the genetic abnormality in population at risk.We have developed a simple, reproducible, rapid and cheap procedure that, using PCR and SSCP, allows the identification of the mutation responsible for Factor V Leiden. Specificity of this method has been tested in 319 samples: 304 normal, 14 heterozygous and 1 homozygous for Factor V Leiden. This assay allows non-isotopic Factor V Leiden identification by using frozen whole blood in 3 h. All these features make this test adequate for routine screening of this mutation in a large number of samples.


1995 ◽  
Vol 74 (05) ◽  
pp. 1381-1382 ◽  
Author(s):  
Hironobu Fujimura ◽  
Jun-ichi Kambayashi ◽  
Morito Monden ◽  
Hisao Kato ◽  
Toshiyuki Miyata

Sign in / Sign up

Export Citation Format

Share Document